1. Home
  2. NUVL vs GBCI Comparison

NUVL vs GBCI Comparison

Compare NUVL & GBCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

N/A

Current Price

$96.50

Market Cap

7.8B

Sector

Health Care

ML Signal

N/A

Logo Glacier Bancorp Inc.

GBCI

Glacier Bancorp Inc.

N/A

Current Price

$43.37

Market Cap

6.3B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
NUVL
GBCI
Founded
2017
1955
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
7.8B
6.3B
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
NUVL
GBCI
Price
$96.50
$43.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
5
Target Price
$135.33
$53.60
AVG Volume (30 Days)
449.1K
921.7K
Earning Date
05-07-2026
04-23-2026
Dividend Yield
N/A
3.04%
EPS Growth
N/A
18.45
EPS
N/A
1.99
Revenue
N/A
N/A
Revenue This Year
N/A
$31.62
Revenue Next Year
$1,165.56
$8.37
P/E Ratio
N/A
$21.85
Revenue Growth
N/A
N/A
52 Week Low
$55.54
$36.76
52 Week High
$113.02
$53.99

Technical Indicators

Market Signals
Indicator
NUVL
GBCI
Relative Strength Index (RSI) 39.83 41.23
Support Level $73.71 $43.81
Resistance Level $107.13 $43.90
Average True Range (ATR) 3.10 1.03
MACD -0.09 0.20
Stochastic Oscillator 21.24 48.04

Price Performance

Historical Comparison
NUVL
GBCI

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About GBCI Glacier Bancorp Inc.

Glacier Bancorp Inc is a regional bank holding company providing commercial banking services to scores of communities through its wholly-owned bank subsidiary, Glacier Bank. The bank operates a multitude of banking offices in Montana, Idaho, Colorado, Utah, Washington, and Wyoming. The bank's various products and services include deposit, loans, and mortgage origination services, among others. The bank predominantly serves individuals, small- to medium-sized businesses, community organizations, and public entities. Glacier emphasizes both internal growth and growth through selective acquisitions. A majority of the bank's loan portfolio is in commercial real estate, while a majority of its net revenue is net interest income.

Share on Social Networks: